Related Experiment Video
Updated: Mar 24, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Evaluation of toxicity on epithelial and tumor cells of biaryl dipeptide tyrosines
Stanley N S Vasconcelos1, Carine C Drewes2, Leonard de Vinci Kanda Kupa2
1Departamento de Farmácia, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo, SP, Brazil.
Abstract:
We report a method to obtain biaryl dipeptide tyrosine via Suzuki-Miyaura and alkynyl dipeptide tyrosine by Sonogashira cross-coupling reactions. Analysis of the biological action of biaryl dipeptide tyrosine 4d compound showed its ability to impair the metabolism and proliferation of SK-Mel-28 human melanoma lineage cells, independently of mitochondrial membrane depolarization, apoptosis and necrosis. Moreover, 4d compound did not cause toxicity to human umbilical vein endothelial cells (HUVEC), suggesting its toxic specificity to cancer cells.
Insights
This study introduces novel biaryl and alkynyl dipeptide tyrosines synthesized using cross-coupling reactions. The biaryl compound selectively targets melanoma cells, inhibiting their growth without harming healthy cells.
Area of Science:
- Organic Synthesis
- Medicinal Chemistry
- Cancer Biology
Background:
- Dipeptide tyrosine derivatives are of interest for their potential therapeutic applications.
- Developing selective anti-cancer agents remains a critical challenge in oncology.
Purpose of the Study:
- To synthesize novel biaryl and alkynyl dipeptide tyrosine compounds.
- To evaluate the anti-cancer activity and specificity of synthesized compounds against human melanoma cells.
Main Methods:
- Suzuki-Miyaura cross-coupling reaction for biaryl dipeptide tyrosine synthesis.
- Sonogashira cross-coupling reaction for alkynyl dipeptide tyrosine synthesis.
- In vitro biological assays using SK-Mel-28 melanoma cells and human umbilical vein endothelial cells (HUVEC).
Main Results:
- Successful synthesis of biaryl and alkynyl dipeptide tyrosine derivatives.
- Biaryl dipeptide tyrosine 4d demonstrated significant impairment of melanoma cell metabolism and proliferation.
- Compound 4d exhibited specificity, showing no toxicity to HUVEC, indicating selective cancer cell targeting.
Conclusions:
- The developed cross-coupling methods provide access to novel dipeptide tyrosine analogues.
- Biaryl dipeptide tyrosine 4d shows promise as a selective anti-melanoma agent.
- Further investigation into the mechanism of action and therapeutic potential of compound 4d is warranted.
